Clinical trial
A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With…
NCT00118638 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00118638 |
|---|---|
| Title | A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy |
| Official title | A Randomized, Double Blind, Active-Controlled Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Anemia, Non-Myeloid Malignancies |
| Intervention type | Drug |
| Interventions | Darbepoetin alfa - 2.25 mcg/kg, Darbepoetin alfa - 500mcg |
| Enrollment | 705 |
| Start date | Mar 1, 2004 |
| Primary completion | Dec 1, 2004 |
| Completion | Jan 1, 2005 |
| First posted | Jul 12, 2005 |
| Last update posted | Apr 29, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: